Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23.
The interaction between the immune system and prostate cancer has been an area of research interest for several decades. The recent U.S. Food and Drug Administration approval of 2 first-in-class proof-of-concept immunotherapies (sipuleucel-T and ipilimumab) has stimulated broader interest in manipulating immunity to fight cancer. In the context of prostate cancer, the immunotherapy strategies that have garnered the most interest are the therapeutic vaccination strategies, exemplified by sipuleucel-T and PROSTVAC-VF, and immune checkpoint blockade of CTLA-4 and PD-1. Improved understanding of the immune responses generated by these strategies and development of predictive biomarkers for patient selection will guide rational combinations of these treatments and provide building blocks for future immunotherapies.
免疫系统与前列腺癌之间的相互作用是几十年来研究的热点领域。最近，美国食品和药物管理局批准了两种首创的概念验证免疫疗法（sipuleucel-T 和 ipilimumab），这激发了人们更广泛地利用免疫来对抗癌症的兴趣。在前列腺癌的背景下，最受关注的免疫治疗策略是治疗性疫苗策略，以 sipuleucel-T 和 PROSTVAC-VF 为代表，以及 CTLA-4 和 PD-1 的免疫检查点阻断。更好地了解这些策略产生的免疫反应，并开发用于患者选择的预测性生物标志物，将指导这些治疗方法的合理联合，并为未来的免疫疗法提供基础。
